RHRihua Huang

Rihua Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rihua Huang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    3-Dimensional Human iPSC-Derived Cardiac Organoids for Antifibrotic Drug Screening

    by Hao Zhang, Rihua Huang, Phung N. Thai, Lu Ren, Rabindra V. Shivnaraine, Wenjuan Zhu, Yuanyuan Dai, Wenqiang Liu, Mengjie Xie, Xiu Liu, et al.


  • Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy

    by Hao Zhang, Rabindra V. Shivnaraine, Lu Ren, Phung N. Thai, Remi Janicot, Wenjuan Zhu, Rihua Huang, Dirk H. Siepe, Chengyi Tu, Wenqiang Liu, et al.

    Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration–approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cell (iPSC)–based platform. Through high-throughput screening, we identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF. Mechanistic studies revealed an atypical adenosine receptor (AR)–dependent signaling pathway in which AR subtypes converge on Gβγ (the βγ subunits of heterotrimeric GTP-binding proteins) to activate phosphoinositide 3-kinase (PI3K)–AKT and yes-associated protein (YAP). CGS suppressed this signaling axis, thereby reducing fibrotic gene expression and fibroblast activation. These findings establish AR-driven Gβγ signaling as a potential therapeutic target for cardiac fibrosis.


  • New approach methodologies: drug screening platform to identify antifibrotic compounds

    by Hao Zhang, Lu Ren, Rihua Huang, Renke Tan, David E. Solow-Cordero, Souhrid Mukherjee, Joseph C. Wu

    Fibrosis is characterized by excessive deposition of extracellular matrix, leading to organ stiffening and progressive dysfunction. Cardiac fibrosis, in particular, is a common feature in ischemic heart failure, genetic cardiomyopathies, diabetes mellitus and aging, which exacerbates cardiac dysfunction and ultimately contributes to increased morbidity and mortality. Despite its clinical burden and importance, there are currently no US Food and Drug Administration-approved drugs that specifically target cardiac fibrosis. This gap is largely due to the lack of reliable translational drug discovery platforms. To address this unmet clinical need, we present our new approach methodology drug screening platform for identifying novel compounds to treat cardiac fibrosis. This high-throughput screening system uses human reporter induced pluripotent stem (iPS) cell-derived cardiac fibroblasts to identify initial hits with potential antifibrotic effects, followed by counter-screening using iPS cell-derived cardiomyocytes to exclude compounds with potential cardiotoxicity. Compared to traditional primary cell-based approaches, our iPS cell-based workflow is robust, scalable and capable of screening ~5,000 compounds within 6–8 weeks. This protocol provides a versatile and efficient platform for phenotypic drug discovery with broad potential for translational applications in medicine.

  • Open Access

    Intensive Glycemic Treatment Mitigates Cardiovascular and Mortality Risk Associated With Cardiac Autonomic Neuropathy in Type 2 Diabetes

    by Huimin Zhou, Yiquan Huang, Peihan Xie, Shaozhao Zhang, Menghui Liu, Zhenyu Xiong, Rihua Huang, Xingfeng Xu, Miaohong Li, Ziwei Zhou, et al.

    Background: Hyperglycemia is one of the proposed risk factors for cardiac autonomic neuropathy (CAN). CAN is associated with increased cardiovascular and mortality risk. But it remains unclear whether cardiovascular and mortality risk associated with CAN is mitigated by intensive glycemic treatment. Methods and Results: This secondary analysis included 7866 patients from the ACCORDION (Action to Control Cardiovascular Risk in Diabetes Follow‐On) study. CAN was defined using ECG‐derived measures. End points included primary outcome (composite of cardiovascular events) and total deaths. During a median follow‐up of 8.9 years, a total of 1341 cardiovascular events and 1364 all‐cause deaths were ascertained. Compared with standard treatment, intensive treatment reduced risk of primary outcome and total deaths among patients with CAN but not among those without CAN. Compared with absence of CAN, the presence of CAN was associated with increased risk of primary outcome and total deaths in the standard group but not in the intensive group. Significant interactions were found between CAN status and treatment arms on risk of primary outcome and total deaths. Incidence rates per 100 person‐years of primary outcome and total deaths were similar between patients without CAN and those with CAN undergoing intensive treatment. Conclusions: Intensive glycemic treatment mitigates cardiovascular and mortality risk associated with CAN and may serve as an effective way in the management of CAN.


  • Open Access

    Equations for Predicting the 10-Year Risk of Atherosclerotic Cardiovascular Disease in Population With Obesity

    by Yi Zhou, Menghui Liu, Zhuohui Chen, Xiaojie Cai, Lixiang He, Jiangjie Lei, Rihua Huang, Shaozhao Zhang, Yiquan Huang, Zhengyu Xiong, et al.


  • Prognostic significance of aortic valve calcification in relation to coronary artery calcification for cardiovascular diseases

    by Han Wen, Rihua Huang, Xinghao Xu, Zhenyu Xiong, Menghui Liu, Yue Guo, Xiaodong Zhuang, Xinxue Liao

    Aims: Both coronary artery calcification (CAC) and aortic valve calcification (AVC) are strongly associated with cardiovascular diseases (CVDs), but data about the prognostic significance of multiple cardiovascular calcifications are limited. We aim to investigate the interaction relationship between AVC and CAC for major events. Methods and results: We included 6695 participants from the Multi-Ethnic Study of Atherosclerosis at baseline and divided them into four groups: (i) no AVC or CAC; (ii) only AVC; (iii) only CAC; and (iv) with CAC and CAC. The Cox regression model and the Kaplan–Meier method were used to analyse CVD outcomes. We evaluated the interaction between AVC and CAC and their added predictive value based on the pooled cohort equations (PCEs). Subgroup analyses were also explored. Among 6695 participants (mean age 62.2 ± 10.2 years, 47.2% male), after follow-up, 943 cases (14.1%) of CVD and 1274 cases (19.0%) of all-cause death occurred. For participants with both AVC and CAC, the risk of CVD significantly increased [hazard ratio = 3.43 (2.69–4.37), P < 0.001], even higher than the sum of the ones with only AVC and only CAC. This trend remained the same for all-cause death and among subgroup analyses. The addictive interaction was statistically significant (P < 0.001). When AVC and CAC were added, the predictive value of PCEs increased. Conclusion: Our results indicated a synergistic interaction between valve calcification and coronary calcification in CVDs. Management for both AVC and CAC may bring health co-benefits in preventing poor outcomes.


  • Open Access

    New Insights into Rate Control: Time in Target Range of Resting Heart Rate and Major Adverse Outcomes in Atrial Fibrillation

    by Yuhui Lai, Xingfeng Xu, Shaozhao Zhang, Rihua Huang, Yiquan Huang, Xiangbin Zhong, Zhenyu Xiong, Yifen Lin, Huimin Zhou, Yue Guo, et al.

    Background: Few studies have examined the relationship between the fluctuation of heart rate control over time and cardiovascular outcomes in patients with atrial fibrillation. Our study sought to evaluate the independent association between time in target range (TIR) of resting heart rate and cardiovascular outcomes in the AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) study. Methods: Target range of resting heart was defined as less than 80 beats per minute (bpm) for both rate and rhythm control groups. Time in target range was estimated over the first 8 months of follow-up using Rosendaal interpolation method. The association between TIR of resting heart rate and cardiovascular outcomes was estimated using adjusted Cox proportional hazards regression models. Results: Time in target range of resting heart rate (months 0 through 8) was 71 ± 34% in the rate control group and 83 ± 27% in the rhythm control group. Each 1-SD increase in TIR of resting heart rate was significantly associated with lower risk of major adverse cardiovascular events after full adjustment for demographics, medical history and history of prior heart surgery, as well as all-cause mortality. Conclusions: Time in target range of resting heart rate independently predicts the risk of cardiovascular outcomes in patients with atrial fibrillation. Long-term maintenance of heart rate on target is of great importance for patients with atrial fibrillation.


  • Long-term physical activity time-in-target range in young adults with cardiovascular events in later life

    by Zihao Huang, Rihua Huang, Xinghao Xu, Ziyan Fan, Zhenyu Xiong, Qi Liang, Yue Guo, Xinxue Liao, Xiaodong Zhuang

    Maintaining long-term guidelines-recommended PA levels may decrease the risk of cardiovascular events in later life, and young adults maintaining that PA level for at least 75% of time may be preferable. Bullet Points


  • Open Access

    Remnant Cholesterol in Young Adulthood Is Associated With Left Ventricular Remodeling and Dysfunction in Middle Age: The CARDIA Study

    by Xinghao Xu, Zhaoyan Wang, Rihua Huang, Yue Guo, Zhenyu Xiong, Xiaodong Zhuang, Xinxue Liao

    BACKGROUND: Recent studies have shown that remnant cholesterol (RC) is associated with incident heart failure; however, its association with left ventricular (LV) structure and function is unclear. We aimed to evaluate the association between RC levels in young adulthood and LV structure and function in middle age. METHODS: We included 3321 participants from the CARDIA study (Coronary Artery Risk Development in Young Adults) at baseline. RC was calculated as total cholesterol minus high-density lipoprotein cholesterol minus calculated low-density lipoprotein cholesterol, and the RC trajectories that followed a similar pattern of change over time were identified using the latent class growth mixture model. LV structure and function were assessed using echocardiography at CARDIA study year 25. Multivariable linear regression models were performed to assess the associations of both baseline and trajectories of RC levels with LV structure and function. RESULTS: Among 3321 participants, the mean age was 24.99±3.62 years: 1450 (43.90%) were male, and 1561 (47.00%) were Black. After multivariate adjustment, higher baseline RC (per SD in log-transformed) was associated with higher LV mass index (β=1.29; P =0.004), worse global longitudinal strain (β=0.19; P P =0.014), lower septal e′ (β=−0.26; P P =0.003), and higher E/e′ (β=0.15; P =0.003). Three RC trajectories were identified during follow-up: low increasing (42.4%), moderate increasing (45.5%), and high increasing (12.1%). Similarly, compared with the low-increasing group, the high-increasing RC trajectory group was related to higher LV mass index, worse global longitudinal strain, lower septal e′, lower lateral e′, and higher E/e′. CONCLUSIONS: Elevated RC levels in young adulthood were related to adverse LV structural and functional alterations in midlife. Long-term trajectories of RC levels during young adulthood help identify individuals at a higher risk for adverse LV remodeling and dysfunction. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00005130.


  • Serum Klotho Modifies the Associations of 25-Hydroxy Vitamin D With All-Cause and Cardiovascular Mortality

    by Zhuohui Chen, Menghui Liu, Xingfeng Xu, Lixiang He, Peng Wang, Xiaojie Cai, Rihua Huang, Shaozhao Zhang, Xinghao Xu, Yuhui Lai, et al.

    Background: The association between 25-hydroxyvitamin D and mortality remains controversial. Klotho, a biomarker of vitamin D activation and metabolism, may play a key role in this association. However, it is unclear whether the association between vitamin D deficiency and mortality risk is modified by klotho levels. Therefore, this study investigated the joint association of serum 25-hydroxyvitamin D [25(OH)D] and klotho with mortality risk in American community-dwelling adults. Methods: A total of 9870 adults from the National Health and Nutrition Examination Survey (2007-2016) were included in our study. Mortality data were ascertained by linking participants to National Death Index records. Cox proportional hazards models were used to assess the association among serum 25(OH)D, serum klotho, and all-cause and cardiovascular disease (CVD) mortality. Results: We found a significant interaction between klotho and serum 25(OH)D in all-cause mortality (P = .028). With klotho > 848.4 pg/mL (risk threshold on mortality), no significant all-cause and CVD mortality risk was observed at any level of serum 25(OH)D. However, with klotho < 848.4 pg/mL, a significant all-cause and CVD mortality risk was observed with serum 25(OH)D < 50 nmol/L [hazards ratio (HR), 1.36; 95% confidence interval (CI), 1.10-1.69; HR, 1.78; 95% CI, 1.16-3.45) and serum 25(OH)D of continuous variable (HR, 0.98; 95% CI, .97-.99; HR, 0.98; 95% CI, .98-.99). In addition, vitamin D metabolism disruption accessed by the combination of decreasing serum 25(OH)D (<50 nmol/L) and klotho (<848.4 pg/mL) was associated with significant all-cause mortality (HR, 1.48; 95% CI, 1.11-1.96) and CVD mortality (HR, 2.36; 95% CI, 1.48-3.75). Conclusions: Vitamin D-associated mortality risk is observed only with concurrently decreasing klotho, indicating that vitamin D metabolism dysfunction increases the risk of mortality. Klotho levels could help predict long-term mortality outcomes and thus may be useful concurrently for guiding vitamin D supplementation therapy decision-making in populations with vitamin D deficiency.